Cancer pioneer Simon Chu's Ride4Research

Hudson Institute

A pioneer in the fight against rare ovarian cancers, Dr Simon Chu, is taking a break from the lab and putting rubber on the road as part of the Ride4Research.

Dr Simon Chu spends his working life searching for cures to rare forms of ovarian cancer, but he is about to spend nine days as part of a group of cyclists riding 900 kilometres to raise funds for more research.

In his work at Hudson Institute of Medical Research Dr Chu specialises in Granulosa Cell Tumour, with much of his funding coming from the Rare Ovarian Cancer Foundation (ROC Inc), and now he's giving back to help raise funds.

Canberra to Melbourne Ride4Research

VIEW VIDEO | WIN News Canberra feature on Ride4Research.

Ride4Research is a 900km bike ride organised by ROC Inc, from Canberra to Melbourne, and this year 16 volunteers are tackling the journey - each with a connection to rare ovarian cancers.

Juvenile Granulosa Cell Cancer (JGCT) is a rare ovarian cancer that typically affects younger females, with Australia's youngest patient diagnosed at just 11 months old, and the oldest at 53 years. Overall, 94% of patients with JGCT are under 30.

Currently there is no cure for JGCT, and research is needed to help understand the disease. The Ride 4 Research will raise funding directly aimed at researching this little-known cancer in the hope of developing an appropriate treatment.

Raising awareness and funding for research

Departing on May 1, the intrepid cyclists will cover a route taking in Canberra, Tumut, Tumbarumba, Tallangatta, Wangaratta, Euroa, Yea and Whittlesea en route to Melbourne to raise awareness and funding.

Ride 4 Research will conclude on 8 May 2022, which is World Ovarian Cancer Day and Mother's Day, at the Yarra Park near the MCG at 9.30am.

For all full list of the scheduled stops, see www.rocinc.org.au/ride-for-research.

Funders | ROC Inc

Hudson Institute communications

t: + 61 3 8572 2697

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.